MASH Clinical Trials in California - Advancing MASH Care and Shaping the Future of Treatment
In the pursuit of medical breakthroughs for Nonalcoholic Steatohepatitis (NASH), FOMAT Medical Research stands at the forefront, dedicated to the advancement of research and discovery of effective treatments. Our unwavering commitment to NASH clinical trials aims to unveil innovative solutions to combat this silent yet impactful liver disease, promising a brighter future for patients around the globe.
Metabolic dysfunction-associated steatohepatitis (MASH)
Metabolic dysfunction-associated steatohepatitis (MASH) is a liver condition marked by excessive fat and inflammation due to metabolic issues like obesity and diabetes. It can worsen to severe liver damage and even cancer. At FOMAT Medical Research, we highlight the urgent need for detailed research to diagnose, treat, and prevent MASH, recognizing its significant effects on individuals and communities.
Why Clinical Trials Are Crucial for MASH Research
Clinical trials are the cornerstone of progress in combating NASH/MASH. These studies are pivotal in addressing the current challenges in NASH diagnosis and management, including the development of non-invasive diagnostic tools, expanding treatment options, and understanding the variability in disease progression. Through clinical trials, FOMAT aims to improve patient outcomes and offer hope to those battling this condition.
Symptoms and Progression of MASH/NASH
Metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), typically starts without symptoms. As it progresses, symptoms such as fatigue, upper abdominal pain, weight loss, nausea, and jaundice may appear. The disease progresses through stages starting from simple steatosis (fatty liver), to steatohepatitis (inflammation and liver damage), to fibrosis (scar tissue formation), and potentially to cirrhosis or liver cancer if untreated.
Causes and Risk Factors
While the exact cause of MASH is unknown, it is associated with several risk factors. Obesity and type 2 diabetes significantly increase the risk, as do high levels of 'bad' LDL cholesterol and metabolic syndrome—a cluster of conditions that includes hypertension and abnormal cholesterol levels. These factors contribute to the excess fat in the liver, leading to MASH.
Complications of NASH/MASH
MASH can lead to severe complications such as cirrhosis, characterized by permanent liver scarring and impaired liver function. This can progress to liver failure or liver cancer, specifically hepatocellular carcinoma. MASH also increases the risk of cardiovascular disease and exacerbates conditions like type 2 diabetes due to increased insulin resistance. Early detection and proactive management are key to preventing these serious outcomes
What are Clinical Trials?
Clinical trials are research studies that involve human participants to evaluate the efficacy and safety of various interventions, such as medications, surgical procedures, or lifestyle adjustments. These studies are essential for confirming whether new treatments are both safe and effective. Specifically regarding Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as Non-Alcoholic Steatohepatitis (NASH), clinical trials explore new treatment options, diagnostic methods, and deeper understandings of the disease. Participating in a clinical trial offers a chance to advance medical knowledge and possibly gain early access to emerging treatments before they are widely available.
Why Participate in Clinical Trials?
Participating in clinical trials offers several benefits, particularly the opportunity to access new treatments for Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as Non-Alcoholic Steatohepatitis (NASH), that are not yet available to the broader public. This can be crucial, especially when current treatments have proven ineffective, potentially offering significant personal health improvements. Additionally, participants contribute valuable data that helps researchers better understand MASH, furthering the development of treatment and care practices for the condition. Engaging in a clinical trial enables individuals to play a key role in advancing new medical interventions that could improve life quality for future patients. Moreover, clinical trials typically provide thorough monitoring by healthcare professionals, offering an additional layer of medical oversight
Our Active Studies
-
NASH/MASH Trial
NASH/MASH, often a silent liver condition, typically remains undetected until it becomes advanced. It begins with an accumulation of fat in the liver and can progress to significant liver injury. Taking early measures is crucial to curb its severity.  Criteria & Qualifications: • Participants need to be aged 18 or older.
Read more
• Must have a diagnosis of Fatty Liver Disease.
 Compensation: Contact us for more information. -
NASH/MASH Study
NASH/MASH is a liver disease with inflammation and damage from fat buildup. If you have NASH/MASH, consider participating in our study to help find new treatments. Criteria & Qualifications: • Must be 18 years or older.
Read more
• Diagnosed with Ulcerative Colitis.
• Is willing to provide medical records.
Compensation: Contact us for more information. -
NASH/MASH
Coming Soon! NASH/MASH is a quiet liver disease that often shows no symptoms until it's severe. It starts with extra liver fat and can lead to serious liver damage. Early action is key to preventing it from getting worse.  Criteria & Qualifications: • Must be over 18 years old.
Read more
• Diagnosed with Fatty Liver Disease.
 Compensation: Contact us for more information. -
NASH/MASH Study
Nonalcoholic fatty liver disease (NAFLD) is a condition where fat accumulates in the liver. NASH, the more severe form, causes swelling and damage to the liver. Currently, there is no existing treatment for NASH/MASH.
Read more
Criteria & Qualifications: • Is at least 18 years of age or older.
• Inflammation and liver damage, also known as Nonalcoholic steatohepatitis (NASH).
• Must be weight stable for 6 months.
 Compensation: Up to $3,000.
Who is FOMAT Medical Research?
FOMAT Medical Research is California's largest research site network, dedicated to advancing clinical research and improving patient outcomes. With an extensive network of research sites and a relentless commitment to innovating healthcare through diversity, FOMAT Medical Research collaborates with industry Sponsors and CROs to accelerate the development of groundbreaking therapies across multiple therapeutic areas. FOMAT is a founding member of hyperCORE International, a super network of fully professionalized research site organizations.
FOMAT's Commitment to NASH Research
FOMAT Medical Research is renowned for its expertise in conducting NASH-related clinical trials. Our commitment to advancing knowledge and discovering new treatments for NASH is unwavering, with several ongoing and completed studies under our belt.
Meet Our Experts
